Hypomagnesaemia among patients with type 2 diabetes mellitus and impaired glucose tolerance and its correlation with glycemic control: a cross-sectional study in a tertiary care hospital of Bangladesh

Mahin Ta, Rahim MAb, Haque WMMb, Qader MAC, Faria Le

ABSTRACT

Background: Hypomagnesaemia is linked to insulin resistance in type 2 diabetes mellitus (T2DM) and chronic diabetic complications. Prevalence of hypomagnesaemia is high in patients with T2DM and multiple studies have shown evidence of effect of serum magnesium (Mg) level on glycaemic control in these patients. The aims of this study were to evaluate the frequency of hypomagnesaemia in hospitalized patients with T2DM and impaired glucose tolerance (IGT) and to evaluate its correlation with glycaemic control.

Methods: This was a cross-sectional study conducted from November, 2016 to March, 2017 in BIRDEM General Hospital. Hypomagnesaemia was defined as serum Mg concentration <0.7 mmol/L. Patients who had acute diarrhea or vomiting in previous 7 days, patients who had chronic diarrhea or malabsorption syndrome or who had recent history of taking diuretics were excluded from the study. Patients’ clinical information were collected using a structured questionnaire and laboratory information were collected from the hospital records.

Results: Total patients were 100, including T2DM (92) and IGT (8). Thirty nine (42.4%) patients with T2DM and five (62.5%) patients with IGT had hypomagnesaemia. The median (IQR) serum Mg level in patients with T2DM was 0.77 (0.6-0.8) mmol/L and IGT was 0.6 (0.52-0.77) mmol/L. HbA1c was higher among patients with hypomagnesaemia than normal Mg level [median (IQR) 9.4 (7.8-12.7) % vs 8.85 (7.2-9.95) %] though it was not significant (p>0.05). The mean fasting blood glucose (FBG) was 9.82 mmol/l in patients with hypomagnesaemia and 9.63 mmol/l in patients with normal serum Mg. Median 2-hour post prandial blood glucose level was 12 (10.4-16.15) mmol/L in hypomagnesaemia group and 11.7 (10.3-14.7) mmol/L in normal Mg group, though the difference was not statistically significant. There was negative correlation between serum Mg and HbA1c, FBG and post prandial blood glucose level (r, -0.075, -0.003, -0.006 respectively). Among the patients with hypomagnesaemia, the percentage of ischemic heart disease (IHD), diabetic retinopathy, diabetic nephropathy and diabetic neuropathy was 31.8%, 36.4%, 43.2% and 34.1% compared to 23.2%, 30.4%, 32.1% and 25% respectively in patients with normal Mg level.

Conclusion: Around half of the patients with T2DM and IGT had hypomagnesaemia and patients with hypomagnesaemia were found to have relatively poor glycemic control and had increased rate of diabetic complications. Although relationship between serum magnesium level and glycemic control was not significant, it indicated the need of further research in this aspect.

Key words: hypomagnesemia, type 2 diabetes mellitus, impaired glucose tolerance.

BIRDEM Med J 2022; 12(3): 207-211

Author information

a. Tasnova Mahin, Associate Consultant, Internal Medicine, Square Hospitals Limited, Dhaka, Bangladesh.
b. Muhammad Abdur Rahim, Wasim Md. Mohosinul Haque, Associate Professor, Department of Nephrology, BIRDEM General Hospital, Dhaka, Bangladesh.
c. Md. Abdul Qader, Associate Consultant, Department of Paediatric Nephrology, Square Hospitals Limited, Dhaka, Bangladesh.
d. Labeeba Faria, Specialist, Nephrology, Square Hospitals Limited, Dhaka, Bangladesh.

Address of correspondence: Tasnova Mahin, Associate Consultant, Department of Internal Medicine, Square Hospitals Limited, Dhaka, Bangladesh. Email:drtasnova@squarehospitals.com

Received: March 24, 2022
Revision received: July 16, 2022
Accepted: August 23, 2022
INTRODUCTION
Globally, over 300 million people suffer from type 2 diabetes mellitus (T2DM). T2DM is characterized by combination of insulin deficiency and insulin resistance. Magnesium is an essential ion in human which is involved in various functions including energy homeostasis, protein synthesis, DNA stability. In healthy individual, serum magnesium is regulated between 0.7-1.05 mmol/L. Magnesium is associated with glucose metabolism, insulin secretion and insulin sensitivity. Magnesium can be found in many foods such as grains, nuts and green leafy vegetables and it plays a key role in many fundamental biological processes as well as glucose metabolism. At the molecular level, it has been suggested that hypomagnesemia may induce altered cellular glucose transport, defective tyrosine kinase activity, insulin receptor autophosphorylation, post receptor impairment in insulin function by intracellular signalling cascade and processing, reduced pancreatic insulin secretion and worsening of insulin resistance in diabetes. In patients with T2DM, prevalence of hypomagnesemia ranges from 14 to 48% compared to 2.5-5% in healthy population. This study aimed to evaluate the frequency of hypomagnesemia in hospitalized patients with T2DM and impaired glucose tolerance (IGT) and correlate with glycemic status and associated diabetic complications.

METHODS
This cross-sectional study was done at the medicine inpatient department of Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM) General Hospital, Dhaka, Bangladesh from November, 2016 to March, 2017. One hundred hospitalized adult patients with T2DM and IGT were included in the study. Patients, who had acute diarrhea or vomiting in previous 7 days, patients who had chronic diarrhea or malabsorption syndrome or who had recent history of taking diuretics were excluded from the study. Serum magnesium level <0.7 mmol/L was labeled as hypomagnesemia. The study protocol was approved by the Institutional Review Board (IRB) of BIRDEM General Hospital, Dhaka, Bangladesh. Data were collected from patients and hospital records after taking informed written consents and were recorded in case record forms. Data were analyzed by Statistical Package for Social Sciences (SPSS) version 20. Qualitative data were expressed in percentage and quantitative data were expressed in mean, median, standard deviation and interquartile range. P value of <0.05 was taken as significant.

RESULTS
Total patients were 100 including 92 T2DM and 8 IGT. Mean age was 61.13 ±11.40 years with 68% being males. Base-line characteristics are shown in Table I.

Table I Baseline characteristics of the patients (N=100)

| Variable               | Results       |
|------------------------|---------------|
| Age (mean± SD) ( in years) | 61.13±11.4    |
| Gender (%)             | 68% male, 32% female |
| Co-morbidities         |               |
| Hypertension (%)       | 86            |
| Ischaemic heart disease (%) | 27            |
| Microvascular complications |            |
| Retinopathy (%)        | 33            |
| Nephropathy (%)        | 37            |
| Neuropathy (%)         | 29            |

Among the study population, 44% patients had hypomagnesemia. Mean serum magnesium level was 0.73±0.16 mmol/L. Among patients with T2DM the frequency of hypomagnesemia was (39/92), 42.4% and among patients with IGT frequency was (5/8) 62.5%. The median (IQR) serum magnesium level in patients with T2DM was 0.77 (0.6-0.8) mmol/L and IGT was 0.6 (0.52-0.77) mmol/L (Figure 1).

Figure 1 Level of serum magnesium (median and IQR) among patients with hypomagnesaemia and normal magnesium levels
Median HbA1c (%) (IQR) was 9.4 (7.8-12.7) in patients with hypomagnesaemia vs 8.85 (7.2-9.95) in patients with normal magnesium level (Figure 2). The difference was not statistically significant (p>0.05).

Figure 2 HbA1c among patients with hypomagnesaemia and normal magnesium level

Mean fasting blood glucose (FBG) level in study population was 9.71 mmol/l and it was 9.82 mmol/l in patients with hypomagnesemia and 9.63 mmol/l in patients with normal serum magnesium level. Mean serum magnesium level in patients with FBG ≤6.0 mmol/l was 0.74 ±0.18 mmol/l and in patients with FBG >6 mmol/l mean serum magnesium was 0.73 ±0.16 mmol/l. But the difference was not statistically significant (p value >0.05). Median 2 hours post prandial blood glucose level was 12 (10.4-16.15) mmol/L in hypomagnesemia group and 11.7 (10.3-14.7) mmol/L in normal magnesium group (Figure 3), though the difference was not statistically significant.

Figure 3 Post-prandial blood glucose levels among patients with hypomagnesaemia and normal magnesium level

There was negative correlation between serum magnesium and HbA1c (r=0.075), FBG (r=0.003) and post prandial blood glucose level (r=0.006) according to Pearson’s formula but p value was not statistically significant (>0.05). Among the patients with hypomagnesaemia, the percentage of ischemic heart disease (IHD), diabetic retinopathy, diabetic nephropathy and diabetic neuropathy was 31.8%, 36.4%, 43.2% and 34.1% compared to 23.2%, 30.4%, 32.1% and 25% respectively in patients with normal magnesium level (Figure 4).

Figure 4 Different complications of diabetes among patients with hypomagnesaemia and normal magnesium level

DISCUSSION

Multiple studies have shown inverse relationship between dietary magnesium intake and risk of T2DM.9 Several studies have shown beneficial effects of magnesium supplementation on insulin sensitivity and glucose metabolism.10-12 A randomized double-blind placebo controlled trial in healthy individuals with prediabetes and hypomagnesemia showed that magnesium supplementation for 3 months reduced hs-CRP levels13, given that inflammation and oxidative stress are important factors in insulin resistance, hypomagnesaemia may contribute to insulin resistance.14,15 Rosangela Spiga et al. did a large prospective cohort study in 2019 where there were 589 participants with a mean follow up time of 5.6 years. It revealed that there was significant negative correlation between magnesium level with FBG and 2 hour post prandial plasma glucose level.16 In our study the negative correlation was not statistically significant, but it may be attributed to small sample size. Haticce Ozcaliskan Ilkay et al. reported in a study higher level of HbA1c, fasting and post prandial plasma glucose in type 2 diabetic patients with hypomagnesemia compared to type 2 diabetic patients with normal magnesium.17 We found similar results in our study.
Arundhati Dasgupta et al. found that hypomagnesemia was associated with poor glycemic control, retinopathy, nephropathy and foot ulcers. In our study we found higher HbA1c, fasting and post prandial blood glucose as well as higher rate of IHD, retinopathy, nephropathy and neuropathy in patients with hypomagnesemia compared to normal magnesium. One study by Barbagallo M et al found that oral magnesium supplementation appears to be useful in T2DM patients with hypomagnesemia to improve insulin resistance, oxidative stress and systemic inflammation. Magnesium is found to be associated with more rapid and permanent decline of renal function. Multiple epidemiological studies have shown inverse relationship between magnesium and risk of developing type 2 diabetes. A randomized double blind control study showed magnesium supplementation improved insulin sensitivity and metabolic control.

The prevalence of hypomagnesemia is 14-48% in patients with T2DM, which means millions of people are affected worldwide. Hypomagnesemia is associated with conditions that are often present in T2DM, including hypertension, hypokalemia and muscle cramps, more clinical attention is necessary to address this problem. Patients with T2DM who are taking diuretics, proton pump inhibitors, calcineurin inhibitors and who suffer from diarrhoea due to diabetic neuropathy are specially at risk of hypomagnesemia and should be closely monitored. Although widespread clinical evidence of the association of hypomagnesemia and T2DM are available, the molecular mechanisms of Mg2+ on insulin secretion and insulin resistance are still not properly understood.

The results of this study indicate that hypomagnesemia may be associated with poor glycemic control as well as increased rate of complications. Limitations of this study are small sample size and it was done in hospitalized patients who may have other risk factors for poor diabetes control. However, the findings are still far from complete and further studies are needed to understand the complicated role of magnesium in diabetes and the role of this nutrient as protective factor against insulin resistance and diabetic complications.

Authors’ contribution: TM and MAR planned the study, TM collected and analyzed data, TM did literature search, TM and MAR drafted manuscript with contribution of WMM, MAQ and LF. All authors read and approved the final manuscript for submission.

Conflict of interest: Nothing to declare.

REFERENCES

1. Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J 2012;27:269-73.
2. deBaij JHF, Hoenderop JGJ, Bindels RJM. Magnesium in man: implications for health and disease. Physiol Rev 2015;95:1-46.
3. Gommers LMM, Hoendrop JGJ, Bindels RJM. Hypomagnesemia in Type 2 Diabetes. Diabetes 2015;65:3-13.
4. Bertinato J, Xiao CW, Ratnayake WMN, Fernandez L, Lavergne C, Wood C, et al. Lower serum magnesium concentration is associated with diabetes, insulin resistance, and obesity in South Asian and white Canadian women but not men. Food Nutr Res 2015; 59: 25974.
5. Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007;2:366-73.
6. Agrawal P, Arora S, Singh B, Manamalli A, Dolia PB. Association of macrovascular complications of type 2 diabetes with serum magnesium levels. Diabetes Metab Syndr 2011; 5: 41-4.
7. Sales CH, Pedrosa LFC, Lima JG, Lemos TMAM, Colli C. Influence of magnesium status and magnesium intake on the blood glucose control in patients with type 2 diabetes. Clin Nutr Edinb Scotl 2011; 30: 359-64.
8. Lecube A, Baena-Fustegueras JA, Fort JM, Pelegrí D, Hernández C, Simó R. Diabetes is the main factor accounting for hypomagnesemia in obese subjects. PLoS ONE 2012; 7: e30599.
9. Dong JY, Xun P, He K, Qin LQ. Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes Care 2011;34: 2116-22.
10. Guerrero-Romero F, Rodriguez-Morán M. Oral magnesium supplementation: an adjuvant alternative to facing the world wide challenge of type 2 diabetes? Cir Cir 2014; 82:282-9.
11. Guerrero-Romero F, Simental-Mendoza LE, Hernández-Ronquillo G, RodríguezMorán M. Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: a double-blind placebo-controlled randomized trial. Diabetes Metab 2015;41:202-7.
12. Rodriguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 2003;26: 1147-52.
13. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebocontrolled trial. Arch Med Res 2014;45:325-30.
14. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008;582:97-105.
15. Henriksen EJ, Diamond-Stanic MK, Marchionne EM. Oxidative stress and the etiology of insulin resistance and type 2 diabetes. Free Radic Biol Med 2011; 51:993-9.
16. Spiga R, Mannino GC, mancuso E, Averta C, Paone C, Rubino M, et al. Are circulating Mg$^{2+}$ levels associated with glucose tolerance profiles and incident type 2 diabetes?. Nutrients 2019;11:2460.
17. OZcaliskan Ilkay H, Sahin H, Tanriverdi F, Samur G. Association between magnesium status, dietary magnesium intake and metabolic control in patients with type 2 diabetes mellitus. J Am Coll Nutr 2019 Nov;38(1):31-9.
18. Dasgupta A, Sarma D, Saikia UK. Hypomagnesemia in type 2 diabetes mellitus. Indian J Endocrinol Metab 2012 Nov;16(6):1000-3.
19. Barbagallo M, Dominguez LJ. Magnesium and type 2 diabetes. World J Diabetes 2015; 6: 1152-7.
20. Pham PC, Pham PM, Pham PA. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol 2005;63:429-36.
21. Rodriguez-Morán M, Guerrero-Romero F. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care 2003;26:1147-52.
22. Chaudhary DP, Sharma R, Bansal DD. Implications of magnesium deficiency in type 2 diabetes; a review. Biol Trace Elem Res 2010;134:119-29.
23. de Baaij JHF, Hoenderop JGJ, Bindels RJM. Magnesium in man: implications for health and disease. Physiol Rev 2015;95:1-46.
24. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012;36:405-13.
25. Lameris AL, Monnens LA, Bindels RJ, Hoenderop JG. Drug-induced alterations in Mg$^{2+}$ homoeostasis. Clin Sci (Lond) 2012;123:1-14.
26. Rahim MA, Mitra P. Serum Magnesium Level of Newly Detected Patients with Glucose Intolerance and Its Comparison with Serum Magnesium Level of Age and Sex Matched Healthy Volunteers. J Medicine 2018;19(2):95-9.